The basic experimental model tested the ability of an infusion of human plasma to expand the normal plasma volume to a hypervolemic state and to maintain this expansion for several hours.
“There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product.
If the C3NeF assay is positive, plasma exchange or infusion should be considered, as should administration of anti-B-cell agents such as rituximab. If a pathologic CFH mutation is found ...